Incidence and Risk Factors of Systemic Adverse Effects and Complications of Ultrasound- and Fluoroscopy-Guided Glucocorticoid Injections : A Retrospective Cohort Study
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVES: The aims of the study are to assess the incidence of systemic adverse effects and complications of ultrasound-guided and fluoroscopy-guided glucocorticoid injections and to identify associated risk factors.
DESIGN: This retrospective cohort study compared participants who received a glucocorticoid injection at the outpatient clinic and participants who had an appointment but did not receive a glucocorticoid injection. Participants were called to verify whether they had experienced any of the predetermined systemic adverse effects and complications. Multiple binary logistic regression was used to identify systemic adverse effect and complication risk factors.
RESULTS: There were 1010 participants in the glucocorticoid injection group and 328 in the nonglucocorticoid injection group. There was no statistically significant difference in the occurrence of systemic infection and decompensated heart failure between the two groups. More participants in the glucocorticoid injection group developed abnormal uterine bleeding and erectile dysfunction, but the differences did not reach statistical significance. Female participants were 1.9 times more likely to develop systemic adverse effects ( P < 0.001). Younger age ( P < 0.001), diabetes ( P = 0.012), and higher glucocorticoid injection doses ( P = 0.024) were also associated with an increased risk of developing systemic adverse effects.
CONCLUSIONS: Identified risk factors for developing glucocorticoid injection systemic adverse effects were younger age, female sex, diabetes, tobacco use, and high glucocorticoid injection doses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
American journal of physical medicine & rehabilitation - 103(2024), 1 vom: 01. Jan., Seite 31-37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lavigne, Alexandre [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 29.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/PHM.0000000000002300 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357587901 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357587901 | ||
| 003 | DE-627 | ||
| 005 | 20240229234200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/PHM.0000000000002300 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM357587901 | ||
| 035 | |a (NLM)37256660 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lavigne, Alexandre |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and Risk Factors of Systemic Adverse Effects and Complications of Ultrasound- and Fluoroscopy-Guided Glucocorticoid Injections |b A Retrospective Cohort Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVES: The aims of the study are to assess the incidence of systemic adverse effects and complications of ultrasound-guided and fluoroscopy-guided glucocorticoid injections and to identify associated risk factors | ||
| 520 | |a DESIGN: This retrospective cohort study compared participants who received a glucocorticoid injection at the outpatient clinic and participants who had an appointment but did not receive a glucocorticoid injection. Participants were called to verify whether they had experienced any of the predetermined systemic adverse effects and complications. Multiple binary logistic regression was used to identify systemic adverse effect and complication risk factors | ||
| 520 | |a RESULTS: There were 1010 participants in the glucocorticoid injection group and 328 in the nonglucocorticoid injection group. There was no statistically significant difference in the occurrence of systemic infection and decompensated heart failure between the two groups. More participants in the glucocorticoid injection group developed abnormal uterine bleeding and erectile dysfunction, but the differences did not reach statistical significance. Female participants were 1.9 times more likely to develop systemic adverse effects ( P < 0.001). Younger age ( P < 0.001), diabetes ( P = 0.012), and higher glucocorticoid injection doses ( P = 0.024) were also associated with an increased risk of developing systemic adverse effects | ||
| 520 | |a CONCLUSIONS: Identified risk factors for developing glucocorticoid injection systemic adverse effects were younger age, female sex, diabetes, tobacco use, and high glucocorticoid injection doses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Nguyen, Don |e verfasserin |4 aut | |
| 700 | 1 | |a Chartrand-Oberoi, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Noyon, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Spiliotopoulos, Stevie |e verfasserin |4 aut | |
| 700 | 1 | |a Kfoury, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Vanasse, Lorence |e verfasserin |4 aut | |
| 700 | 1 | |a Chamieh, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Bouhadana, Haïm |e verfasserin |4 aut | |
| 700 | 1 | |a Boudier-Revéret, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Mares, Christopher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of physical medicine & rehabilitation |d 1996 |g 103(2024), 1 vom: 01. Jan., Seite 31-37 |w (DE-627)NLM012918512 |x 1537-7385 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:31-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/PHM.0000000000002300 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 1 |b 01 |c 01 |h 31-37 | ||